Annals of Oncology 21 (Supplement 5): v59–v64, 2010
doi:10.1093/annonc/mdq166clinical practice guidelines
Hepatocellular carcinoma: ESMO Clinical Practice
Guidelines for diagnosis, treatment and
follow-up
S. Jelic1 & G. C. Sotiropoulos2
On behalf of the ESMO Guidelines Working Group*
1Internal Medicine Service, Institute of Oncology and Radiology, Belgrade, Serbia; 2Department of General, Visceral and Transplantation Surgery, University Hospital
Essen, Essen, Germany
incidence
Hepatocellular carcinoma (HCC) is the fifth most common
cancer in men and eighth most common cancer in women
worldwide, resulting in at least 500 000 deaths per year. It
accounts for 90% of all liver cancers. Its crude incidence in the
European Union is 8.29/100 000. Areas such as Asia and sub-
Saharan Africa with high rates of infectious hepatitis have
incidences as high as 120 cases per 100 000. It is four to eight
times more common in men and usually associated with
chronic liver injury [hepatitis B (HBV), hepatitis C (HCV) and
alcoholic cirrhosis]. Chronic infection with HBV in the setting
of cirrhosis increases the risk of HCC 100-fold. Some 5%–30%
of individuals with HCV infection develop chronic liver disease,
�30% progress to cirrhosis, and in these, 1%–2% per year
develop HCC. Co-infection with HBV further increases the
risk. Alcohol abuse in the setting of chronic HCV infection
doubles the risk of HCC compared with HCV infection
alone. Median age at diagnosis is between 50 and 60 years. In
Africa and Asia, age at diagnosis is substantially younger, the
cancer occurring in the fourth and fifth decades of life,
respectively.
surveillance
Patients at high risk for HCC should be considered for, and
offered to be entered into surveillance programmes. These
include all cirrhotic HBV carriers; non-cirrhotic patients with
high HBV DNA concentration; patients with HCV-related or
alcocholic cirrhosis, as well as patients with several rare
disorders. Surveillance should be performed using
ultrasonography at 6- to 12-month intervals, associated or not
with a-fetoprotein (AFP) determination, in order to detect
early HCC amenable to surgical treatment with curative intent
[II, B]. Despite correct surveillance, there are, however, still no
data confirming that these advantages in detection of earlier
lesions produce an improvement in long-term survival, and
cirrhotic patients Child–Pugh B and C may have rather limited
options for curative treatment.
diagnosis
Tumors are multifocal in the liver in 75% of cases at
diagnosis. Diagnosis is usually made by history, physical
examination, imaging (ultrasound, MRI or CT scan showing
a liver mass consistent with HCC) and optionally elevated
serum AFP (>400 ng/ml), because AFP is elevated in only
50%–75% of cases. A suspicious lesion on the sonogram
generally requires additional imaging studies to confirm the
stage of the tumour and sensitivity for detection of small
nodules may be low. The addition of arterial phase imaging to
conventional CT scanning increases the number of tumour
nodules detected, but in nodular cirrhotic livers the sensitivity
to detect HCC is low. The overall sensitivity of MRI is similar
to that of triphasic CT scan, but in patients with nodular
cirrhotic livers MRI has better sensitivity and specificity.
Confirmation of diagnosis is made by fine needle aspiration or
biopsy. Elevation of AFP >400 ng/ml can be used instead of
fine needle cytology for diagnosis of HCC in patients with
liver cirrhosis and a focal hypervasular liver lesion (>2 cm) in
at least one imaging technique. Patients with potentially
resectable liver mass and AFP >400 ng/ml should undergo
surgery without preoperative fine needle aspiration cytology
or biopsy. Any deterioration in liver function in a patient with
known liver cirrhosis of any aetiology should raise a suspicion
of HCC.
As an increasing number of cirrhotic patients and/or HBV/
HCV carriers are entered into surveillance programmes, it is
most likely that in a substantial number of patients, classical
echosonography will be the initial imaging technique raising
a suspicion of HCC. Afterwards the size of lesions and the
presence or not of cirrhosis will influence the sequence of tests
used to diagnose HCC. Suspect nodules <1 cm should be
*Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L.
Taddei 4, CH-6962 Viganello-Lugano, Switzerland;
E-mail: clinicalrecommendations@esmo.org
Approved by the ESMO Guidelines Working Group: November 2007, last update
November 2009. This publication supercedes the previously published version—Ann
Oncol 2009; 20 (Suppl 4): iv41–iv45.
Conflict of interest: The authors have reported no conflicts of interest.
ª The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
at St Jude Childrens Research Hospital on Septem
ber 4, 2010
a
n
n
o
n
c.o
xfordjournals.org
D
ow
nloaded from
followed with ultrasound at intervals of 3–6 months; nodules
between 1 and 2 cm in a cirrhotic liver should be investigated
with at least two dynamic studies (triphasic CT scan,
ultrasound or MRI with contrast). If two techniques show
a typical appearance of HCC, the nodule should be interpreted
as such; if that is not the case, the lesion should be either
biopsied whenever possible or extirpated at the discretion of the
physician. Nodules >2 cm with a typical feature of HCC on
a dynamic imaging technique, as well as any nodule associated
with AFP concentration >400 ng/ml or rising AFP on
sequential determinations need not be biopsied but should
be considered as proven HCC, and appropriate available
treatment modalities should be started.
staging and risk assessment
Staging should include X-ray of chest (alternatively CT scan)
and CT scan (alternatively MRI) of the abdomen. Imaging
studies for eventual other tumour localizations should be
performed as needed according to the clinical context. CT scan
of the chest and bone scintigraphy have to be performed in
transplant candidates. Tumors should be staged according to
AJCC staging criteria/TNM system, although it appears to be of
less predictory value than the CLIP (Cancer of the Liver Italian
Program) and the BCLC (Barcelona Clinic Liver Cancer)
staging. In fact, in most patients with HCC we are dealing with
two diseases, each one of them independently determining our
treatment possibilities and final patient outcome: the cancer
itself and the underlying liver disease. Thus, an optimal staging
system targeting treatment modalities should include grading
of both. Transplant candidates must be evaluated according to
the current listing criteria.
The fibrolamellar variant is not associated with cirrhosis of any
aetiology, is not associated with increased AFP serum
concentrations and, if resectable, has amore favourable prognosis.
For patients being considered for liver transplantation,
MELD (Model for End-stage Liver Disease) score is mandatory.
Child–Pugh grade A patients and selected favourable grade B
ones should be evaluated for specific treatment options. For the
fibrolamellar variant, local treatment modalities are the only
ones to be considered, as there is no documented
chemotherapy regimen or biological agent that has shown any
activity.
treatment plan
The treatment of every patient with HCC should always be
discussed and planned by a multidisciplinary team. The
treatment plan should be based on the presence or absence of
liver cirrhosis, extent of disease, growth pattern of tumour,
hepatic functional reserve and patient’s performance status.
The applicable treatment possibilities include surgical (liver
resection, liver transplantation), ablative (transarterial
chemoembolization, radiofrequency ablation) and medical
(sorafenib) modalities. Due to the MELD-score-oriented
allocation policy during recent years, selected Child C patients
with HCC within the Milan criteria may be discussed for
liver transplantation. Child–Pugh grade C patients should be
offered only supportive care if their tumour exceeds current
listing criteria.
surgical modalities
liver resection
Liver resection is the first-line option for patients with
localized resectable tumours in the non-cirrhotic liver, or in
selected patients with Child–Pugh A liver cirrhosis. A 3-year
survival of 54% is reported in patients with HCC in the non-
cirrhotic liver after performance of R0 resections, i.e.
resections with tumour-free surgical margins. At the
moment there are no recommendations concerning eventual
adjuvant treatment after R1 resection. In the case of localized
intrahepatic tumour recurrence after liver resection, re-
evaluation for surgery has to be considered. For relapses
not amenable to surgery, ablative treatments alone, or
sorafenib may be applied. For diffuse intrahepatic tumour
recurrence after liver resection in the non-cirrhotic liver, the
possibility of liver transplantation may be discussed in
selected cases as an extended indication, but only in
specialized centres.
liver transplantation
Liver transplantation offers the best long-term effective
treatment for patients with HCC in cirrhosis. Patients that
fulfill Milan criteria (single tumour £5 cm; two or three
tumours, none >3 cm; no vascular invasion), or the expanded
University of California San Francisco criteria (UCSF criteria:
single tumour £6.5 cm; two or three tumours, none >4.5 cm;
or total tumour diameter £8cm; no vascular invasion) may
have a 3-year survival of up to 88%. The expansion of the
tumour-specific criteria for transplantation is a topic of
discussion and disputation in hepatological and transplant
congresses. Recently, the ‘up-to seven criteria’ (in the absence
of microvascular invasion, seven is the result of the sum of
size in cm and number of tumours for any given HCC) were
proposed in an effort to include additional HCC patients as
transplant candidates; however, the radiological recognition
of microvascular invasion is a topic of debate. Several studies
suggested poor post-transplant results for HCC patients with
elevated AFP (>400 ng/ml), age >60 years and MELD score
>20. Post-transplant treatment with mTOR inhibitors
(sirolimus, everolimus) in order to reduce the risk of recurrence
are currently evaluated in prospective studies. In the case of
localized intrahepatic recurrence, all modalities from liver
resection, re-transplantation up to medical treatment must be
evaluated. In the case of extrahepatic recurrence, sorafenib is the
treatment of choice for selected patients.
At present, according to the accepted transplant policy, liver
transplantation can be performed for patients with HCC
fulfilling Milan or UCSF criteria. Liver transplantation for
patients with HCC exceeding these criteria may be discussed in
large-volume centres, having the possibility either to perform
split liver transplants or to accept marginal grafts, or to perform
live donor liver transplantation. Such transplant indications
have to be evaluated individually by the corresponding ethic
committees and transplant boards.
clinical practice guidelines Annals of Oncology
v60 | Jelic & Sotiropoulos Volume 21 | Supplement 5 |May 2010
at St Jude Childrens Research Hospital on Septem
ber 4, 2010
a
n
n
o
n
c.o
xfordjournals.org
D
ow
nloaded from
ablative modalities
transarterial chemoembolization
Transarterial chemoembolization (TACE) represents an
accepted treatment of HCC in the setting of cirrhosis, either as
a palliative technique per se, or as a ‘bridging’ modality before
liver transplantation. In the latter case, the goal is to downstage
patients whose tumours exceed accepted transplant listing
criteria, or to achieve local tumour control for patients who
meet the tumour listing criteria while on the waiting list for
liver transplantation (if waiting list exceeds 6 months). The
TACE principle is intra-arterial injection of cytotoxic drug
combinations like doxorubicin and/or cisplatin and/or
mitomycin into the hepatic artery, followed by lipiodol
injection, gelfoam for vessel occlusion and degradable
microspheres [II, A].
An aggressive ablation therapy in association with a short
transplant waiting time has the potential to optimize the
curative intent of liver transplantation in selected cirrhotic
patients. According to the local extension of the disease and the
hepatic functional reserve, TACE may be performed as
a ‘complete’ one a selective one, or a super-selective one, with
application through a microcatheter. Contraindications to
TACE include Child–Pugh C liver cirrhosis, presence of
multifocal bilobar tumour spread, presence of extrahepatic
metastases, portal vein thrombosis or arterio-portal fistula.
radiofrequency ablation
Radiofrequency ablation (RFA) represents a widely applied
method to treat HCC in a palliative intent, or as a ‘bridging’ to
liver transplantation. It may be performed under ultrasonography
or CT guidance, or during laparoscopic and open surgical
procedures. It has some more limitations in comparison with
TACE, such as the number of the nodules that may be treated (up
to three in most centres) or the maximal tumour diameter of the
nodules (up to 5 cm). Effective treatment has been achieved,
when a 100% tumour necrosis is present. However, it is unlikely
to reach this goal with tumours exceeding the above mentioned
diameter or number of tumour nodules.
other ablative procedures
Percutaneous ethanol injection (PEI), cryotherapy, microwave
coagulation therapy are alternative modalities to RFA, which
have not met such a wide application as RFA. PEI is indicated
in patients with fewer than three or four tumour nodules,
maximum 5 cm in size [III, B]. The efficacy of PEI is clearly
inferior to RFA in tumours >5 cm [II, B].
yttrium-90 microsphere radioembolization
Yttrium-90 (Y90) microsphere radioembolization is a recently
FDA-approved, non-surgical procedure used to treat inoperable
Table 2. CLIP classification
Parameter Score
Child–Pugh
A 0
B 1
C 2
Tumour morphology
Uninodular and extension <50% of liver 0
Multinodular and extension <50% of liver 1
Massive or extension ‡50% of liver 2
Alpha fetoprotein
<400 ng/ml 0
>400 ng/ml 1
Macrovascular invasion
No 0
Yes 1
Risk assessment is based on Pugh’s modification of Child’s grading of liver
function.
CLIP scores range from 0 to 6 (CLIP 0 = 0 points, CLIP 1 = 1 point. etc.).
Table 3. Child–Pugh classification of severity of liver disease
Parameter Points assigned
1 2 3
Ascites Absent Slight Moderate
Bilirubin, mg/dl £2 2–3 >3
Albumin, g/dl >3.5 2.8–3.5 <2.8
Prothrombin time
Seconds over control 1–3 4–6 >6
INR <1.8 1.8–2.3 >2.3
Encephalopathy None Grade 1–2 Grade 3–4
A total score of 5–6 is considered grade A (well-compensated disease), 7–9
is grade B (significant functional compromise) and 10–15 is grade C
(descompensated disease).
Table 1.
TNM staging criteria for HCC
T1 Solitary tumour without vascular invasion
T2 Solitary tumour with vascular invasion or multiple
tumours none >5 cm
T3 Multiple tumours >5 cm or tumour involving a major
branch of the portal or hepatic vein(s)
T4 Tumor(s) with direct invasion of adjacent organs other
than the gallbladder or with perforation of visceral
peritoneum
N0 Indicates no nodal involvement
N1 Indicates regional nodal involvement
M0 Indicates no distant metastasis
M1 Indicates metastasis present beyond the liver
Stage grouping
Stage I T1 + N0 + M0
Stage II T2 + N0 + M0
Stage IIIA T3 + N0 + M0
Stage IIIB T4 + N0 + M0
Stage IIIC TX + N1 + M0
Stage IVB TX + NX + M1
Staging systems such as CLIP or BCLC that include staging of liver cirrhosis
may improve prediction of the ultimate prognosis of HCC patients.
Specifically, BCLC staging system (which includes the Okuda staging)
appears more useful than the TNM for planning future patient
management since it takes into account tumour stage, liver function and
physical status.
Annals of Oncology clinical practice guidelines
Volume 21 | Supplement 5 |May 2010 doi:10.1093/annonc/mdq166 | v61
at St Jude Childrens Research Hospital on Septem
ber 4, 2010
a
n
n
o
n
c.o
xfordjournals.org
D
ow
nloaded from
HCC. This innovative procedure delivers targeted, internal
radiation therapy directly to the tumour. There are some
promising reported results for this technique either as a ‘bridging’
option before other treatment modalities (partial hepatectomy,
liver transplantation) or as a main therapy for patients with
diffuse intrahepatic tumour spread. Once the catheter is properly
placed in the hepatic artery, microspheres, which contain the
radioactive Y90, are released into the hepatic bloodstream. These
microspheres lodge in the smaller blood vessels that feed the
tumour. In addition to preventing blood flow to the tumour, the
microspheres emit radiation that helps to destroy the cancerous
cells. Due to the targeted nature of this approach, it can deliver
a much more potent dose of radiation than conventional
radiation therapy. The radioactivity of Y90 continually decreases
over a 2-week period, at which time the radioactivity is essentially
gone. Number and size of tumours does not need to be
determined for treatment to be effective. Treatment with Y90
microspheres has the advantage of being able to treat all
intrahepatic HCC lesions, including otherwise undetected
tumours. It may also be the alternative to TACE in selected
patients with contraindications for TACE. Extrahepatic metastases
are also a contraindication to Y90 microsphere radioembolization.
radiotherapeutical modalities
Management of patients with invasion of the portal vein or
inferior vena cava invasion is debatable. Investigational but
clinically applicable options for selected patients (large solitary
tumour with a few satellites and a sufficient amount of healthy
liver to be spared) include:
� Radioembolization with Y90 microspheres as previously
described for patients with branch or lobar portal vein
thrombosis (PVT).
� Three-dimensional conformal radiotherapy (3D-CRT) 30–60
Gy for patients with no or Child–Pugh grade A cirrhosis and
tumour invasion of the inferior vena cava, or patients with
PVT of the main branch.
� Portal vein stenting followed by 3D-CRT and TACE for
patients with main portal vein tumour thrombosis.
medical modalities
Until recently there has been no standard medical therapy for
advanced HCC. The positive results of a Phase III study called
the Sorafenib Hepatocarcinoma Assessment Randomized
Protocol (SHARP), which assessed the use of sorafenib in
patients with unresectable HCC introduced this medication as
the first promising one in the systemic treatment of HCC.
Sorafenib induced in a previous Phase II study response in 8%
and disease control in 41% of patients. In two Phase III studies
with patients with Child–Pugh grade A liver disease, it extended
survival for 2.8 months as compared with placebo, and is more
and more widely accepted as a standard first-line option for
systemic treatment [I, A].
Systemic chemotherapy should not be included in standards
of care but may be discussed with and offered to selected
candidates for systemic treatment if no other options are locally
available. Systemic chemotherapy containing anthracyclines (if
bilirubin normal and hepatic reserve adequate) was reported to
have a prospect of a 10% response rate but no survival benefit.
Cisplatin-based combinations were reported to improve
response rate but again with no survival benefit as compared
with supportive care alone [III, C]. In the PIAF regimen
Table 4. Definition of the BCLC staging for HCC
Stage PST Tumor status Liver function status
Tumor stage Okuda stage
Stage A: early HCC 0
A1 0 Single, <5 cm I No portal hypertension and
normal bilirubin
A2 0 Single, <5 cm I Portal hypertension and
normal bilirubin
A3 0 Single, <5 cm I Portal hypertension and
ab